Summary: Reasons for performing study: The use of anti‐ulcer medication in the neonatal intensive care unit (ICU) is common due to the concern for development of catastrophic gastric ulcer disease. In man, however, the use of acid‐suppressive medication has been shown in some studies to be a substantial risk factor for the development of Clostridium difficile‐ associated diarrhoea (CDAD), bacteraemia and neonatal sepsis. Objective: The purpose of the study reported herein is to evaluate the influence of anti‐ulcer medications on the development of diarrhoea in the neonatal foal. Hypothesis: The use of anti‐ulcer medication does not alter the incidence of diarrhoea in foals treated in an ICU. Methods: The records of 1710 foals from 6 different equine hospitals were examined and the use of anti‐ulcer drugs was recorded. The presence of in‐hospital acquired diarrhoea, CDAD, Clostridium perfringens ‐associated diarrhoea, neonatal sepsis and salmonellosis were documented. In addition, the presence of gastric ulceration, duration of hospital stay and short‐term outcome were examined. Results: The use of anti‐ulcer medications increased the odds of in‐hospital diarrhoea by 2.0 (95% CI 1.4–2.9; P<0.0001), relative to the use of no anti‐ulcer medication. There was no significant association of anti‐ulcer medication with CDAD (P = 0.3189) (OR 2.0; 95% CI 0.4–9.5). Further, results indicated that decreased prevalence of gastric ulceration was not associated with use of anti‐ulcer drugs among foals in the study for which these data were known (P = 0.5522). Conclusions: Use of anti‐ulcer drugs increases the odds of developing diarrhoea, and may not reduce the incidence of gastric ulceration in hospitalised equine neonates. Potential relevance: The use of anti‐ulcer drugs in neonatal foals being treated in a hospital setting should be carefully evaluated on an individual basis to determine if such use is warranted.
1 January 2011 in Journal of Veterinary Internal Medicine
Objective—To compare clinical, clinical pathology, and outcome variables between geriatric and nongeriatric horses. Design—Retrospective case-control study. Animals—690 horses (345 horses ≥ 20 years old and 345 horses > 1 and < 20 years old) examined at a referral hospital. Procedures—Medical records were examined, and data collected included horse description, diagnosis, outcome, and CBC and serum biochemical analysis results. Cases were horses ≥ 20 years old, and controls were horses > 1 and < 20 years old. Results—Mean ± SD age was 23.9 ± 4.6 years for cases and 9.2 ± 3.6 years for controls. Arabian and pony breeds were significantly overrepresented in the geriatric group, compared with the control group. Diagnoses related to the digestive system, musculoskeletal system, and respiratory system were most common in this hospital population overall (cases and controls). Colic was the most common health problem overall. Digestive system disorders were significantly more prevalent among cases. Short-term survival rates for most categories of colic were no different for cases than for controls, with the exception of the category idiopathic colic. Considering all conditions, cases were significantly more likely to be nonsurvivors than were controls. Minor differences in serum biochemical results were found in some disease subcategories. Geriatric horses with colic were not more commonly euthanized than were adult nongeriatric horses. Conclusions and Clinical Relevance—Results indicated that in this population of horses in a referral hospital, age was associated with the prevalence of specific disease conditions. Few differences between cases and controls were found in serum biochemical values.
The ability of ponazuril to prevent or limit clinical signs of equine protozoal myeloencephalitis (EPM) after infection with Sarcocystis neurona was evaluated. Eighteen horses were assigned to 1 of 3 groups: no treatment, 2.5 mg/kg ponazuril, or 5.0 mg/kg ponazuril. Horses were administered ponazuril, once per day, beginning 7 days before infection (study day 0) and continuing for 28 days postinfection. On day 0, horses were stressed by transport and challenged with 1 million S. neurona sporocysts per horse. Sequential neurologic examinations were performed, and serum and cerebrospinal fluid were collected and assayed for antibodies to S. neurona. All horses in the control group developed neurologic signs, whereas only 71 and 40% of horses in the 2.5 and 5.0 mg/kg ponazuril groups, respectively, developed neurologic abnormalities. This was significant at P = 0.034 by using Fisher exact test. In addition, seroconversion was decreased in the 5.0 mg/kg group compared with the control horses (100 vs. 40%; P = 0.028). Horses with neurologic signs were killed, and a post-mortem examination was performed. Mild-to-moderate, multifocal signs of neuroinflammation were observed. These results confirm that treatment with ponazuril at 5.0 mg/kg minimizes, but does not eliminate, infection and clinical signs of EPM in horses.
Eighteen normal horses were assigned to 1 of 3 treatment groups to investigate the effects of IM or intrathecal (IT) administration of ovalbumin on serum and cerebrospinal fluid (CSF) antibody production. Horses of group 1 were injected intramuscularly with ovalbumin and adjuvant, while horses in treatment groups 2 and 3 received ovalbumin intrathecally or intravenously, followed by IM injection as in group 1. Serum and CSF antibody titers were tested in group I every 30 days for 4 months, while serum and CSF were collected in group 2 and 3 horses at postvaccination day 60. Horses of group 1 (IM) developed a serum antibody titer that peaked at postadministration day 60 (1:24,320 +/- 7,680) (mean +/- I SEM). Anti-ovalbumin antibodies were detected in CSF, and titers paralleled that of the serum, although at a much lower concentration (peak, 1:166 +/- 87). Horses of groups 2 and 3 developed significantly (P = .02) lower serum titers (1:720 and 1:2,067, respectively), but the difference in CSF titers did not achieve statistical significance (P = .06). The results confirm that antigen-specific antibody can be found in the CSF of horses in which antigen is not administered intrathecally. This may affect the interpretation of CSF analysis in diseases such as equine protozoal myeloencephalitis. Further, the findings suggest that IT injection of the soluble antigen ovalbumin induces a state of antigenic tolerance in the horse. The clinical significance of this finding remains unknown at this time.